Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update November 13, 2025
Sitryx presents new preclinical data highlighting PKM2 as a promising metabolic target for the treatment of atopic dermatitis at the Inflammatory Disease Skin Summit 2025 November 13, 2025
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update November 13, 2025
Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC November 10, 2025
Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares November 10, 2025
